Advertisement

Topics

Latest "Aimmune Therapeutics" News Stories

12:49 EDT 24th June 2018 | BioPortfolio

Here are the most relevant search results for "Aimmune Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Aimmune Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Aimmune Therapeutics for you to read. Along with our medical data and news we also list Aimmune Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aimmune Therapeutics Companies for you to search.

Showing "Aimmune Therapeutics" News Articles 1–25 of 6,400+

Extremely Relevant

Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, ...

www.wallstequities.com/registration Aimmune Therapeutics Brisbane, Californiaheadquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of 2.02 million Read more...


Jayson Dallas Leaves Ultragenyx for CEO Post at Aimmune

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: RARE) in Novato, CA. Dallas succeeds Stephen Dilly, who last year announced his plans to retire from Aimmune. The company says Dilly will continue to serve as an […]

Investors not nutty about Aimmune on digesting allergy data

An initial jump has been followed by a deeper drop in the share value of US biotech Aimmune Therapeutics…


Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy

BRISBANE, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that the results of its...

Active-Investors: Wired News - Aimmune Therapeutics' Peanut Allergy Drug AR101 Met Primary Endpoint in Pivotal Phase-3 Clinical Trial

Stock Monitor: Cyanotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Aimmune Therapeutics, Inc. (NASDAQ: A...

BRIEF — Aimmune trading higher on full PALISADE publication

US biotech Aimmune Therapeutics has published full results from its 554-patient Phase III PALISADE trial…

DBV and Aimmune poised to dominate peanut allergy market

Last week, the top two contenders for first peanut allergy immunotherapy to market—DBV Technologies and Aimmune Therapeutics—presented to investors at...Read More... The post DBV and Aimmune poised to dominate peanut allergy market appeared first on Drug Development Technology.

Relevant

Aimmune’s Peanut Allergy Drug Hits Study Goals, FDA Filing Planned

Peanuts rank among the top foods that spark allergic reactions, prompting schools to ban peanut butter sandwiches and travelers to decline airline snacks. Aimmune Therapeutics aims to help with a drug that makes people less sensitive to peanuts. On Tuesday, Aimmune (NASDAQ: AIMT) announced that its drug met the main goals of a late-stage study, […]

Aimmune’s peanut allergy drug hits PhIII trials

A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.

Aimmune Jumps On Phase III Peanut Allergy Trial Data

Aimmune Therapeutics announced late-stage trial results that showed its peanut allergy therapy was effective in more than 67 percent of juvenile patients.

Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

— Presentation on Wednesday, January 10, 2018, at 7:30 a.m. Pacific Time — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference in ...

Public offering nets $165mm for Aimmune

Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $165mm through a public offering of 5.5mm common shares at $3...

Public offering nets $190mm for Aimmune

Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $190mm through a public offering of 6.3mm common shares (incl...

Aimmune's peanut allergy drug meets main goal, shares surge

(Reuters) - U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

Aimmune to file peanut allergy treatment by year-end

Biotech company Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following its major phase 3 trial success. Aimmune saw its shares surge last month after the positive topline results from its PALISA...

Aimmune Therapeutics: Insider Buying Alert

Aimmune's peanut allergy drug meets main goal of key study

(Reuters) - U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Reader Inquiry: How Has The Thesis Changed For Aimmune Therapeutics?

Aimmune Therapeutics (AIMT) Investor Presentation - Slideshow

Aimmune Therapeutics: Special Situation Biotech Opportunity

Aimmune Therapeutics (AIMT) Phase 3 PALISADE Trial Top - Slideshow

Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in May and June: Event: Bank of America Merrill Lynch Healthcare ConferenceDate: May 16, 2018P...

Aimmune knocks down DBV with positive peanut results

The peanut allergy space heats up as Aimmune reports strong data for its late-stage treatment.

Aimmune Therapeutics (AIMT) Presents At 38th Nasdaq Investor Conference - Slideshow

Aimmune Therapeutics to Participate in Four Investor Conferences in March

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in March: Event: 30th Annual ROTH ConferenceDate: Monday, March 12, 2018Presentation Time: 3:3...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks